Mostra i principali dati dell'item

dc.contributor.authorAydillo, Teresa
dc.contributor.authorEscalera, Alba
dc.contributor.authorStrohmeier, Shirin
dc.contributor.authorAslam, Sadaf
dc.contributor.authorSánchez Céspedes, Javier
dc.contributor.authorAyllón Barasoain, Juan 
dc.contributor.authorRoca Oporto, Cristina
dc.contributor.authorPérez Romero, Pilar
dc.contributor.authorMontejo, Miguel
dc.contributor.authorGavalda, Joan
dc.contributor.authorMuñoz, Patricia
dc.contributor.authorLópez Medrano, Francisco
dc.contributor.authorCarratala, Jordi
dc.contributor.authorKrammer, Florian
dc.contributor.authorGarcía Sastre, Adolfo
dc.contributor.authorCordero, Elisa
dc.date.accessioned2023-11-10T13:45:57Z
dc.date.available2023-11-10T13:45:57Z
dc.date.issued2020
dc.identifier.issn2666-3791
dc.identifier.urihttp://hdl.handle.net/10259/7993
dc.description.abstractHemagglutination-inhibitory antibodies are usually highly strain specific with little effect on infection with drifted or shifted strains. The significance of broadly cross-reactive non-HAI anti-influenza antibodies against conserved domains of virus glycoproteins, such as the hemagglutinin (HA) stalk, is of great interest. We characterize a cohort of 40 H1N1pmd09 influenza-infected patients and identify lower respiratory symptoms (LRSs) as a predictor for development of pneumonia. A binomial logistic regression of log10 pre-existing antibody values shows that the probability of LRS occurrence decreased with increased anti-HA full-length and stalk antibody ELISA titers. However, a multilevel logistic regression model adjusted by other potential serocorrelates demonstrates that only antibodies directed against the stalk of HA correlate with protection from lower respiratory infection, limiting disease progression. Our predictive model indicates that a threshold of protective immunity based on broadly cross-reactive HA stalk antibodies could be feasible.en
dc.description.sponsorshipThis work was supported by the Programa de Investigación sobre gripe A/H1N1, Instituto de Salud Carlos III, Ministerio. de Ciencia e Innovación (GR09/0041); the Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III, co-financed by the European Development Regional Fund “A way to Achieve Europe” ERDF; the Spanish Network for Research in Infectious Diseases (REIPI RD06/0008 to E.C.); NIAID grants P01AI097092 and U19AI135972; CRIP (Center for Research on Influenza Pathogenesis), an NIAID-funded Center of Excellence on Influenza Research and Surveillance (CEIRS; contract HHSN272201400008C); and SEM-CIVIC, an NIAID-funded Collaborative Influenza Vaccine Innovation Center (contract 75N93019C00051 to A.G.-S. and F.K.).en
dc.format.mimetypeapplication/pdf
dc.language.isoenges
dc.publisherCell Presses
dc.relation.ispartofCell Reports Medicine. 2020, V. 1, n. 8, 100130es
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectInfluenza antibodiesen
dc.subjectCorrelates of protectionen
dc.subjectTransplant patientsen
dc.subjectViral pneumoniaen
dc.subject.otherMedicinaes
dc.subject.otherMedicineen
dc.subject.otherMicrobiologíaes
dc.subject.otherMicrobiologyen
dc.subject.otherEnfermedades infecciosases
dc.subject.otherCommunicable diseasesen
dc.titlePre-existing Hemagglutinin Stalk Antibodies Correlate with Protection of Lower Respiratory Symptoms in Flu-Infected Transplant Patientsen
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.relation.publisherversionhttps://doi.org/10.1016/j.xcrm.2020.100130es
dc.identifier.doi10.1016/J.XCRM.2020.100130
dc.journal.titleCell Reports Medicinees
dc.volume.number1es
dc.issue.number8es
dc.page.initial100130es
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones


Files in questo item

Thumbnail

Questo item appare nelle seguenti collezioni

Mostra i principali dati dell'item